I 
118TH CONGRESS 
1ST SESSION H. R. 3248 
To amend title XVIII of the Social Security Act to increase price transparency 
of clinical diagnostic laboratory tests under the Medicare program. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 11, 2023 
Mrs. MILLER-MEEKS (for herself and Ms. DEGETTE) introduced the following 
bill; which was referred to the Committee on Energy and Commerce, and 
in addition to the Committee on Ways and Means, for a period to be sub-
sequently determined by the Speaker, in each case for consideration of 
such provisions as fall within the jurisdiction of the committee concerned 
A BILL 
To amend title XVIII of the Social Security Act to increase 
price transparency of clinical diagnostic laboratory tests 
under the Medicare program. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Diagnostic Lab Test-
ing Transparency Act’’. 
VerDate Sep 11 2014 
19:03 May 24, 2023
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H3248.IH
H3248
kjohnson on DSK79L0C42PROD with BILLS
SEC. 2. INCREASING PRICE TRANSPARENCY OF CLINICAL 
DIAGNOSTIC 
LABORATORY 
TESTS 
UNDER 
THE MEDICARE PROGRAM. 
Section 1846 of the Social Security Act (42 U.S.C. 
1395w–2) is amended— 
(1) in the header, by inserting ‘‘AND ADDI-
TIONAL
REQUIREMENTS’’ after ‘‘SANCTIONS’’; 
and 
(2) by adding at the end the following new sub-
section: 
‘‘(c) PRICE TRANSPARENCY REQUIREMENT.— 
‘‘(1) IN
GENERAL.—Beginning January 1, 
2025, each provider of services or supplier that is 
available to furnish any specified clinical diagnostic 
laboratory test under this title shall— 
‘‘(A) make publicly available on an Inter-
net website the information described in para-
graph (2) with respect to each such specified 
clinical diagnostic laboratory test that such pro-
vider or supplier is so available to furnish; and 
‘‘(B) ensure that such information is up-
dated not less frequently than annually. 
‘‘(2) INFORMATION DESCRIBED.—For purposes 
of paragraph (1), the information described in this 
paragraph is, with respect to a provider of services 
VerDate Sep 11 2014 
21:31 May 24, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H3248.IH
H3248
kjohnson on DSK79L0C42PROD with BILLS
or supplier and a specified clinical diagnostic labora-
tory test, the following: 
‘‘(A) The discounted cash price for such 
test (or, if no such price exists, the gross 
charge for such test). 
‘‘(B) The deidentified minimum negotiated 
rate in effect between such provider or supplier 
and any group health plan or group or indi-
vidual health insurance coverage for such test. 
‘‘(C) The deidentified maximum negotiated 
rate in effect between such provider or supplier 
and any such plan or coverage for such test. 
‘‘(3) INCLUSION
OF
ANCILLARY
SERVICES.— 
Any price or rate for a specified clinical diagnostic 
laboratory test available to be furnished by a pro-
vider of services or supplier made publicly available 
in accordance with paragraph (1) shall include the 
price or rate (as applicable) for any ancillary item 
or service (such as specimen collection services) that 
would normally be furnished by such provider or 
supplier as part of such test, as specified by the Sec-
retary. 
‘‘(4) ENFORCEMENT.— 
‘‘(A) IN GENERAL.—In the case that the 
Secretary determines that a provider of services 
VerDate Sep 11 2014 
19:03 May 24, 2023
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H3248.IH
H3248
kjohnson on DSK79L0C42PROD with BILLS